Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

NHS England

This public procurement record has 2 releases in its history.

Award

16 Jan 2026 at 12:42

Award Notice
Tender

08 Sep 2025 at 14:23

Tender Notice
Summary of the contracting process

This public procurement involves NHS England, represented by NHS Arden and Greater East Midlands Commissioning Support Unit, undertaking the process for commissioning Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adults with melanoma. The focus is on health services, with the process utilizing an open procedure under the Health Care Services (Provider Selection Regime) Regulations 2023. Contracts will be awarded across seven regions in England, including London, East of England, and North West, among others. Significant dates include a service commencement on 1st May 2025 and the contract duration lasting five years with an optional four-year extension. The notice to award is planned to be formalized according to NHS England governance, following the evaluation criteria focusing heavily on quality and innovation, along with integration, collaboration, and social value.

The tender presents substantial opportunities for businesses specialising in healthcare and cell therapy, particularly those with expertise in melanoma treatment and cellular therapies like Lifileucel. This opportunity is geared towards established providers with necessary accreditations and licenses such as the Human Tissue Authority licence and Joint Accreditation Committee accreditations. By participating, businesses can significantly expand their service offerings across multiple high-value contracts, each possessing a lifetime value of approximately £11,876,000. This procurement not only targets the expansion of service provision across diverse geographic locations but also aims to tackle health inequalities, hence businesses with a focus on social value and innovation may find a particularly good fit.

How relevant is this notice?

Notice Information

Notice Title

Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)

Notice Description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults). <br/><br/>Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy<br/>Unit (ITU).<br/><br/>Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752<br/><br/>The treatment is complex to administer, requiring surgical expertise for tumour<br/>resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.<br/><br/>The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:<br/>Lot 1: London<br/>Lot 2: East of England<br/>Lot 3: South East<br/>Lot 4: South West<br/>Lot 5: Midlands<br/>Lot 6: North East and Yorkshire<br/>Lot 7: North West<br/><br/>This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.<br/><br/>As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.<br/><br/>The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Lot Information

Lot 1 - London

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London.

The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 2 - East of England

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.

The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 3: South East

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.

The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 4: South West

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.

The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 5: Midlands

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.

The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 6: North East & Yorkshire

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.

The approximate lifetime value of the contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Lot 7: North West

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).

Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).

Lifileucel is being assessed via NICE's technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752

The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.

The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West

This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.

As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.

The approximate lifetime value of each contract is PS11,876,000, subject to the number of patients treated.

The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).

Options: Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-0595dd
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/003869-2026
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£142,512,000 £100M-£1B
Lots Value
£142,512,000 £100M-£1B
Awards Value
Not specified
Contracts Value
£11,876,000 £10M-£100M

Notice Dates

Publication Date
16 Jan 20267 months ago
Submission Deadline
13 Oct 2025Expired
Future Notice Date
Not specified
Award Date
16 Dec 20258 months ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Supplier Information

Number of Suppliers
12
Supplier Names

Barts Health NHS Trust

Cambridge University Hospitals NHS Foundation Trust

Guy's and St Thomas' NHS Foundation Trust

Oxford University Hospitals NHS FT

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST

The Christie NHS Foundation Trust

The Newcastle upon Tyne Hospitals NHS Foundation Trust

The Royal Marsden NHS Foundation Trust

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

University College London Hospitals NHS Foundation Trust

University Hospitals Bristol and Weston NHS Foundation Trust

University Hospitals Southampton

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...